TickerTain
TickerTain
NewsroomShortsPortfolioConvergence
NewsroomShortsPortfolioConvergence
$ANTHROPIC·$MA····$INTC····$BLUE-ORIGIN·$SPCX····$CRWV····$CRM····$MSFT····$NVDA····$ORCL····$CURSOR·$AAPL····$OPENAI·$AMZN····$UBER····$GOOGL····$META····$TSLA····$DATABRICKS·$PERPLEXITY·$LYFT····$NBIS····$TSM····$LITE····$ANDURIL·
$ANTHROPIC·$MA····$INTC····$BLUE-ORIGIN·$SPCX····$CRWV····$CRM····$MSFT····$NVDA····$ORCL····$CURSOR·$AAPL····$OPENAI·$AMZN····$UBER····$GOOGL····$META····$TSLA····$DATABRICKS·$PERPLEXITY·$LYFT····$NBIS····$TSM····$LITE····$ANDURIL·
←

jack dent

T2 · manager / operator

Co-founder of Chai Discovery, a full-stack AI drug discovery company building 3D atomic models for molecule design. Raised $400M at $3.8B valuation from Index, Kleiner Perkins, Sequoia, Dimension. Models deployed in discovery programs at Eli Lilly, Novartis, Pfizer.

1 call·1 name·100% bull·last heard 2 months ago·TBPN
track record

no scored calls yet — needs a stated position or a categorical verdict, with a matured window vs SPY

top calls

highest conviction · one per company
1sthigh conviction
$CHAI-DISCOVERYChai Discoveryposition

Chai Discovery raises $400M at $3.8B valuation

Dent said Chai Discovery raised $400 million at a $3.8 billion valuation, with major checks from Index, Kleiner Perkins, Sequoia, and Dimension.

TBPN2026-07episode →

most discussed · click a bar to filter

  • $CHAI-DISCOVERY

recurring themes

  • AI Drug Discovery1
1 total
$CHAI-DISCOVERY
Chai Discovery
HIGHjack dent·TBPN·2 months ago·IBM Nukes, Demis Govt Plan, Clanker Whales, Paramount WBD Deep Dive· position
Chai Discovery raises $400M at $3.8B valuation
Dent said Chai Discovery raised $400 million at a $3.8 billion valuation, with major checks from Index, Kleiner Perkins, Sequoia, and Dimension.
"So we got uh yeah we we raised $400 million at a $3.8 billion valuation. We're um super lucky to be partnered uh with Index, Kleiner, Parkkins, Sequoia, and Dimension um who are t…"
108:25
9
AI Drug Discoverytailwind
Atomic-level generative models cross from research curiosity to core pharma discovery engines in 2025
Chai Discovery's 3D atomic models achieved zero-shot antibody design in mid-2025, moving success rates from 0.1% to production deployment at Eli Lilly, Novartis, Pfizer. Scientists now solve in hours targets that consumed careers. Pharma R&D spend ($5-15B/year per top company) dwarfs semiconductor R&D, creating a massive, durable TAM. The feedback loop between wet-lab validation and model retraining creates a compounding data advantage.